AzurRx BioPharma, Inc.

AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. Our therapeutic products will be administered to patients as oral non-systemic biologics. The company currently has two products in its pipeline: MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients) and AZX1101, a recombinant enzyme for the prevention of hospital-acquired C.difficile infections. The company is headquartered in New York City, with scientific operations in Langlade, France.

Bank Name AzurRx BioPharma, Inc.
Stock Exchange NASDAQ
Symbol AZRX
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
CEO Mr. Johan M. Spoor
Employees 13
Registered Year 2014